Department of Neurological Surgery, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.
Am J Physiol Heart Circ Physiol. 2013 Jul 15;305(2):H182-91. doi: 10.1152/ajpheart.00138.2013. Epub 2013 May 17.
The presence of urocortins (UCNs) and corticotropin-releasing factor (CRF) receptors has been reported in the hypothalamic arcuate nucleus (ARCN). We have previously reported that UCNs are involved in central cardiovascular regulation. Based on this information, we hypothesized that the ARCN may be one of the sites where UCNs exert their central cardiovascular actions. Experiments were done in artificially ventilated, adult male Wistar rats anesthetized with urethane. Unilateral microinjections (30 nl) of UCN1 (0.12-2 mM) elicited decreases in mean arterial pressure (MAP) and heart rate (HR). Maximum cardiovascular responses were elicited by a 1 mM concentration of UCN1. Microinjections of UCN2 and UCN3 (1 mM each) into the ARCN elicited similar decreases in MAP and HR. UCN1 was used as a prototype for the other experiments described below. HR responses elicited by UCN1 were significantly attenuated by bilateral vagotomy. Prior microinjections of NBI-27914 (CRF-1 receptor antagonist) and astressin (CRF-1 receptor and CRF-2 receptor antagonist) (1 mM each) into the ARCN significantly attenuated the cardiovascular responses elicited by UCN1 microinjections at the same site. Microinjections of UCN1 into the ARCN decreased efferent renal sympathetic nerve activity. It was concluded that microinjections of UCN1, UCN2, and UCN3 into the ARCN elicited decreases in MAP and HR. Decreases in MAP, HR, and renal sympathetic nerve activity elicited by UCN1 microinjections into the ARCN were mediated via CRF receptors. Bradycardic responses to UCN1 were mediated via the activation of vagus nerves, and decreases in MAP may be mediated via decreases in sympathetic nerve activity.
存在的urocortins ( UCNs )和促肾上腺皮质激素释放因子( CRF )受体已被发现在下丘脑弓状核( ARCN )。我们先前的研究报告说, UCNs 参与中枢心血管调节。基于这一信息,我们假设, ARCN 可能是其中之一, UCNs 发挥其中心心血管作用的部位。实验是在人工通气,成年雄性 Wistar 大鼠麻醉用氨基甲酸乙酯。单侧微注射( 30nl ) UCN1 ( 0.12-2mm )诱发平均动脉压( MAP )和心率( HR )下降。最大的心血管反应引起的 1mm 的浓度UCN1 。微注射 UCN2 和 UCN3 (各 1mm )到 ARCN 诱发类似的 MAP 和 HR 下降。 UCN1 作为原型,下面描述的其他实验。心率反应引起的 UCN1 明显减弱双侧迷走神经切断术。事先微注射 NBI-27914 ( CRF-1 受体拮抗剂)和 astressin ( CRF-1 受体和 CRF-2 受体拮抗剂) (各 1mm )到 ARCN 明显减弱心血管反应引起的 UCN1 微注射在同一地点。微注射 UCN1 到 ARCN 减少传出肾交感神经活动。研究结果表明,微注射 UCN1 , UCN2 和 UCN3 到 ARCN 诱发 MAP 和 HR 下降。 MAP 下降, HR ,和肾交感神经活动引起的 UCN1 微注射到 ARCN 介导通过 CRF 受体。心率减慢对 UCN1 介导通过激活迷走神经,而 MAP 的下降可能是通过减少交感神经活动介导的。